Department of Occupational Heath, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3004-561 Coimbra, Portugal.
Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3004-561 Coimbra, Portugal.
Vaccine. 2022 Jan 28;40(4):650-655. doi: 10.1016/j.vaccine.2021.12.014. Epub 2021 Dec 11.
The SARS-CoV-2 pandemic was responsible for the death of millions of people around the world, which accelerated the study of vaccines. The BNT162b2 mRNA COVID-19 is a messenger RNA vaccine that encodes the spike protein of the virus. However, the duration of the protection conferred by this vaccine and factors associated with immune responses require validation in large cohorts.
Here, we present data of humoral immune response to vaccination in4264 healthcare workers, tested before (T0) and 15 and 90 days (T1 and T2, respectively) following vaccination.Peripheral blood was collected for immunological analysis using the Quant SARS-CoV-2 IgG II Chemiluminescent Microparticle Immunoassay (CMIA) to determine anti-spike IgG, receptor binding domain (RBD), S1 subunit of SARS-CoV-2.
At T0, 96·8% (n = 4129) of participants had IgG antibodies non-reactive to anti-SARS-CoV-2. Fifteen days after completing the vaccination, the IgG overall median titer was significantly elevated (21·7x10AU/mL). Both for uni- and multivariate logistic regression analyses women presented higher antibody levels than men, independent of age. Titers were significantly altered among age groups, decreasing by each increase in 10-year of age. At 3 months after completing the vaccination, anti-SARS-CoV-2 IgG titers were 6·3-fold diminished. This real-world post-vaccination data confirmed production of a frequent and elevated anti-SARS-CoV-2 IgG titers, associated with high protection rates. Females and younger participants had higher titer 15 days after vaccination, and despite the significant reduction from 15-to-90 days, those with higher pre-vaccination titers maintained higher levels throughout the remaining timepoints.
These findings support the need to track humoral immunity kinetics to uncover viral susceptibility and eventually implement re-vaccination, particularly in groups prone to lower humoral immune response.
No external funding was received to conduct this study.
SARS-CoV-2 大流行导致了全世界数百万人死亡，这加速了疫苗的研究。BNT162b2 mRNA COVID-19 是一种信使 RNA 疫苗，可编码病毒的刺突蛋白。然而，这种疫苗提供的保护持续时间以及与免疫反应相关的因素需要在大样本中进行验证。
在这里，我们介绍了 4264 名医护人员接种疫苗后的体液免疫反应数据，在接种前（T0）以及接种后 15 天（T1）和 90 天（T2）分别进行了测试。使用 Quant SARS-CoV-2 IgG II 化学发光微粒子免疫分析法（CMIA）采集外周血进行免疫分析，以确定抗刺突 IgG、受体结合域（RBD）、SARS-CoV-2 的 S1 亚基。
在 T0 时，96.8%（n=4129）的参与者的 IgG 抗体对 SARS-CoV-2 无反应。接种疫苗后 15 天，总 IgG 中位数滴度显著升高（21.7x10AU/mL）。无论是单变量还是多变量逻辑回归分析，女性的抗体水平均高于男性，且与年龄无关。在年龄组中，滴度差异显著，每增加 10 岁，滴度就会降低。接种疫苗后 3 个月，抗 SARS-CoV-2 IgG 滴度下降了 6.3 倍。这些真实世界的接种后数据证实，产生了频繁且升高的抗 SARS-CoV-2 IgG 滴度，与高保护率相关。接种后 15 天，女性和年轻参与者的滴度更高，尽管从 15 天到 90 天滴度显著降低，但那些具有较高预接种滴度的参与者在剩余的时间点保持了较高的水平。
这些发现支持了跟踪体液免疫动力学的必要性，以揭示病毒易感性，最终实施重新接种，特别是在那些容易产生较低体液免疫反应的群体中。
该译文仅为示例，不代表最终译文。
Zotero 插件